综述:肠道微生物组对溃疡性结肠炎药物治疗的影响
本综述通过靶向检索PubMed和Embase的临床与临床前研究,汇总肠道微生物组如何调节溃疡性结肠炎(UC)药物的疗效与药代动力学。微生物群通过代谢活性化合物、调节宿主免疫反应及影响局部药物吸收与清除来改变药物暴露和作用,个体间微生物组组成与功能差异可解释部分药物反应异质性。基线微生物组特征与UC治疗结局相关并可能预测治疗反应,提示微生物组指导的精准治疗潜力。
要点
- 肠道微生物组通过代谢药物、调节免疫和影响吸收清除来改变UC药物暴露与作用。
- 个体间微生物组差异可解释UC药物反应、耐久性和不良反应的异质性。
- 基线微生物组特征与UC治疗结局相关,可能预测治疗反应。
核心结论
- 肠道微生物组是UC药物治疗反应中的活跃变量,理解微生物-药物关系可能提高UC治疗的精准性。
研究设计与样本
- 本综述通过靶向PubMed和Embase检索,纳入探索微生物组在UC药物治疗中作用的临床和临床前研究。
主要发现
- 肠道微生物群落通过代谢活性化合物、改变宿主免疫反应、影响局部药物吸收和清除来改变UC药物暴露和作用。
- 个体间微生物组组成和功能差异可能解释药物反应、耐久性和不良反应谱的部分异质性。
- 临床研究显示基线微生物组特征可与UC治疗结局相关,并可能预测治疗反应。
临床怎么用
- 理解微生物组-药物关系可能改善UC治疗的精准性,支持开发微生物组指导的干预措施。
- 可将微生物组视为治疗反应中的活跃变量,为未来药物开发和临床试验设计提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ulcerative colitis (UC) is a chronic immune-mediated condition of the gastrointestinal tract with highly variable treatment responses. Current therapies focus on suppressing inflammation through aminosalicylates, corticosteroids, immunomodulators, biologics, and small molecules, yet many patients experience suboptimal outcomes, including non-response, partial response, or loss of efficacy over time. This variability has prompted increasing attention to the gut microbiome as a contributing factor. AIMS: This review aimed to compile the current evidence on how the gut microbiome modulates the efficacy and pharmacokinetics of UC therapies, including mechanisms of microbial drug metabolism and host-microbe interactions that affect immune regulation. METHODS: Clinical and preclinical studies exploring the role of the microbiome in UC pharmacotherapy were identified through targeted PubMed and Embase searches. RESULTS: Microbial communities in the gut alter UC drug exposure and action by metabolising active compounds, modifying the host immune response, and influencing local drug absorption and clearance. Differences in microbiome composition and function between individuals may explain some of the heterogeneity in drug response, durability and adverse effect profiles. Clinical studies now show that microbiome characteristics at baseline can correlate with UC treatment outcomes and may even predict therapeutic response. CONCLUSIONS: Understanding these microbiome-drug relationships may improve the precision of UC therapy, support the development of microbiome-guided interventions, and inform future drug development and clinical trial design. Recognising the microbiome as an active variable in treatment response reframes pharmacology in UC as not only drug- and host-dependent but also shaped by the dynamic microbial environment of the gut.
引用
- Collins K, Kamath S, Davis RH, et al. Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy. Aliment Pharmacol Ther. 2026. PMID: 42387267. doi:10.1111/apt.70826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。